Stephanie Kornan
Vice President of Investor Relations, Communications and Commercial Strategy, Innate Pharma
Replay available
Innate Pharma S.A. (IPHA) Q4 2025 Earnings Call
Innate Pharma S.A. (NASDAQ: IPHA) Q4 2025 earnings conference call, held 2026-03-26. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Jonathan Dickinson
Chief Executive Officer (CEO), Innate Pharma
Sonia Quarantino
Chief Medical Officer (CMO), Innate Pharma
Yanis Morel
Chief Operating Officer (COO), Innate Pharma
Frédéric Lombard
Chief Financial Officer (CFO), Innate Pharma
Swayam Pakula Ramankath
Analyst, MHC Wainwright
Dana Gray Bosch
Analyst, Leerink Partners
Yigit Mukherjee
Analyst, BTIG
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Innate Pharma Sa Class A.
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.138 Ladies and gentlemen, thank you for joining us and welcome to the Innate Pharma Full 00:00:05.138 -- 00:00:10.145 Year 2025 Earnings Call. After today's prepared remarks, we will host 00:00:10.145 -- 00:00:14.731 a question and answer session. If you would like to ask a question, please raise your 00:00:14.731 -- 00:00:19.918 hand. If you have dialled into today's call, please press star 9 to raise your hand 00:00:19.918 -- 00:00:25.147 and star 6 to unmute. I will now hand the conference over to Stephanie Kornan, 00:00:25.147 -- 00:00:30.237 Vice President of Investor Relations, Communications and Commercial Strategy 00:00:30.237 -- 00:00:35.082 at Innate Pharma. Please, Stephanie, go ahead. 00:00:35.907 -- 00:00:41.204 Thank you. Good morning and good afternoon everyone and thank you for joining 00:00:41.204 -- 00:00:46.451 us for Innate Pharma's full year 2025 business update and financial 00:00:46.451 -- 00:00:51.639 results conference call. The press release and today's presentation are available on 00:00:51.639 -- 00:00:55.786 the investor relations section of our website. 00:00:55.786 -- 00:01:00.798 Before we begin, I would like to remind everyone that today's presentation 00:01:00.798 -- 00:01:05.589 includes forward-looking statements based on current expectations. 00:01:05.589 -- 00:01:10.942 These statements involve risks and uncertainties that could cause actual results 00:01:10.942 -- 00:01:13.884 to differ materially. 00:01:14.315 -- 00:01:20.021 I will briefly cover today's agenda. Our CEO, Jonathan Dickinson, 00:01:20.021 -- 00:01:23.705 will begin with a strategic overview and outlook. 00:01:23.705 -- 00:01:29.311 We will then share updates on our three priority programs, L'Aquitamab, 00:01:29.311 -- 00:01:31.033 ...